Biotechnology company Dermata Therapeutics has announced the dosing of its first patient in a Phase 2 atopic dermatitis study with its lead compound DMT210.
DMT210 is a novel, anti-inflammatory topical gel targeting multiple cytokines in the skin. The cytokines are responsible for causing itchy, red, swollen and cracked skin in most atopic dermatitis patients.
The trail DMT210-002 is a 28-day Phase 2, multicentre, double-blind, vehicle controlled study.
In this clinical trial, the company will assess the safety, tolerability and efficacy of twice-daily dosings of DMT210 in 25 mild-to-moderate atopic dermatitis patients.
The effectiveness of this drug will be calculated through the individual signs and symptoms of atopic dermatitis, investigator's global assessment and Atopic Dermatitis Severity Index.
The company expects to receive top line results by the first half of 2017.
Dermata president and CEO Gerald Proehl said: “Adults and children are seeking better and safer treatments for their atopic dermatitis because it significantly affects their daily lives, including interrupting sleep, disturbing work or school and causing social anxiety.
“We hope that DMT210 can be a safe and effective first-line therapy to help alleviate the daily struggles these patients suffer from and allow them to live a more normal life."
Dermata Therapeutics focuses on developing new and innovative products to treat a variety of dermatological diseases.